Clinical trials: Deficiency Disease
Human Immunodeficiency Virus (HIV) Prophylaxis
Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women
This study will evaluate the hypothesis that intravaginal rings (IVRs) can safely and in a sustained fashion, deliver the antiretroviral (ARV) drugs - tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and maraviroc (MVC)…
- Trial name
- NCT02431273
- Testing
- TDF IVR, TDF-FTC IVR, TDF-FTC-MVC IVR
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Auritec Pharmaceuticals
HIV Infection
Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)
This study seeks to determine the public health impact of providing rapid HIV test kits to men who have sex with men (MSM) so they may test themselves at their convenience.
- Trial name
- NCT02067039
- Testing
- OraQuick in home & Sure Check HIV tests
- Where
- United States
- Volunteers
- 2,665 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Hiv, HIV Infections
HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
This study aims to evaluate the prevalence of previously undiagnosed HIV infection in the hospital setting (across various medical or surgical departments) among individuals exhibiting at least one HIV indicator condition…
- Conditions
- Hiv, HIV Infections, AIDS
- Trial name
- HIV-HOTE (NCT06282328)
- Testing
- HIV test
- Where
- Italy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Castagna Antonella
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
The main purpose of this study is to examine the effect of tipranavir combined with ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in people who have been receiving the same dose of…
- Trial name
- BUTI (NCT00486330)
- Testing
- Buprenorphine, Tipranavir and ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
Iron Deficiency Anaemia, Inflammatory Bowel Disease
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)
The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active ulcerative colitis (UC).
- Conditions
- Iron Deficiency Anaemia, Inflammatory Bowel Disease, Ulcerative Colitis
- Trial name
- AEGIS-1 (NCT01340872)
- Testing
- ST10-021
- Volunteers
- 128 people
- Sponsor
- Shield Therapeutics
HIV/AIDS
Leveraging mHealth and Peers to Engage African- Americans and Latinxs in HIV Care (LEAN)
This is a pragmatic randomized controlled study comparing existing linkage to care and retention (LTCR) services to an mHealth-enhanced linkage to care and retention (mLTCR) protocol.
- Trial name
- NCT03934437
- Testing
- mLTCR, LTCR
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Johns Hopkins University
HIV Infections, Opioid-Related Disorders
SIRI Checklist: An Integrated Hospital Model to Optimize HIV Prevention in Persons Who Inject Drugs
The purpose of this study is to develop and test a serious injection-related injections (SIRI) checklist aimed at increasing evidence-based treatment for rural people who use drugs (PWUD) including innovative, long-acting…
- Conditions
- HIV Infections, Opioid-Related Disorders, Pre-Exposure Prophylaxis (PrEP)
- Trial name
- SHAPE (NCT05480956)
- Testing
- SIRI Checklist, Enhanced Peer Recovery Coach, SIRI Checklist + Enhanced Peer Recovery Coach
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
- Trial name
- CBZ (NCT01379469)
- Testing
- Drug-Carbamazepine (Tegretol XR)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human…
- Trial name
- VOYAGE-1 (NCT03222583)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 48 sites in China, Singapore and 1 more
- Volunteers
- 546 people
- Sponsor
- AbbVie
Hypophosphatasia
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone.
- Trial name
- NCT01176266
- Testing
- asfotase alfa
- Where
- 23 sites in United States, Australia and 10 more
- Volunteers
- 69 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
This is a prospective, non-interventional, multi-center study, in participants with clinical indication of Human Immunodeficiency Virus (HIV)-1 infection.
- Trial name
- URBAN (NCT03754803)
- Testing
- HIV symptom distress module (SDM) questionnaire, HIV treatment satisfaction questionnaire (TSQ)
- Where
- 18 sites in Germany
- Volunteers
- 376 people
- Sponsor
- ViiV Healthcare
Alpha1-antitrypsin Deficiency
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
The purpose of the study is 2-fold: (1) to evaluate the safety and potential immunogenicity of GLASSIA following intravenous (IV) administration via in-line filtration; and (2) to assess the effects of GLASSIA augmentation…
- Trial name
- NCT02525861
- Testing
- GLASSIA
- Where
- 18 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Baxalta now part of Shire
HIV Infections
Combination Vaccination Before HIV Treatment Interruption
The purpose of this study is to determine if vaccination before a structured treatment interruption (STI) is associated with an improvement in immune function, resulting in a delayed and reduced rebound in the amount of HIV virus…
- Trial name
- NCT00212888
- Testing
- Remune and ALVAC
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Fanconi Anemia
Pilot Study of Metformin for Patients With Fanconi Anemia
This is a single institution, open-label, single arm pilot study of Metformin in patients with Fanconi Anemia (FA) and cytopenias with the primary endpoint of hematologic response.
- Trial name
- NCT03398824
- Testing
- metformin HCl
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Boston Children's Hospital
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
IFN-Gamma Therapy, CGD Gene Mutation
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
Background: Chronic granulomatous disease (CGD) is an immunodeficiency disease in which white blood cells are unable to kill certain bacteria and fungi.
- Conditions
- IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease
- Trial name
- NCT01147042
- Testing
- IFN-gamma
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
Antiretroviral therapy (ART) dramatically reduces Human Immunodeficiency Virus (HIV) replication leading to restoration of immune function and a near normal life expectancy, but treatment is lifelong and there is no cure.
- Trial name
- NCT03198559
- Testing
- Disulfiram, (National Drug Code) NDC 0378-4141-01, Vorinostat, NDC 00006-0568-40
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- University of Melbourne
Mesopic Vision, Night Vision Loss
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
- Trial name
- LYNX-2 (NCT06349759)
- Testing
- phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Opus Genetics, Inc
Acquired Immune Deficiency Syndrome, AIDS
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a…
- Conditions
- Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT00814879
- Testing
- Raltegravir, Atazanavir, Standard treatment regimen
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.